Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Impact of Reduced Vancomycin MIC on Clinical Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia

So-Youn Park, In-Hwan Oh, Hee-Joo Lee, Chun-Gyoo Ihm, Jun Seong Son, Mi Suk Lee, Mi-Na Kim
So-Youn Park
Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Koreaa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
In-Hwan Oh
Department of Preventive Medicine, Division of Infectious Diseases, Kyung Hee University School of Medicine, Seoul, Republic of Koreab
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hee-Joo Lee
Department of Laboratory Medicine, Division of Infectious Diseases, Kyung Hee University School of Medicine, Seoul, Republic of Koreac
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chun-Gyoo Ihm
Department of Nephrology,d Division of Infectious Diseases, Kyung Hee University School of Medicine, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Seong Son
Department of Internal Medicine,e Kyung Hee University School of Medicine, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mi Suk Lee
Department of Internal Medicine,e Kyung Hee University School of Medicine, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mi-Na Kim
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Koreaf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01137-13
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Vancomycin has been a key antibiotic agent for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. However, little is known about the relationship between vancomycin MIC values at the higher end of the susceptibility range and clinical outcomes. The aim of this study was to determine the impact of MRSA bacteremia on clinical outcomes in patients with a vancomycin MIC near the upper limit of the susceptible range. Patients with MRSA bacteremia were divided into a high-vancomycin-MIC group (2 μg/ml) and a low-vancomycin-MIC group (≤1.0 μg/ml). We examined the relationship between MIC, genotype, primary source of bacteremia, and mortality. Ninety-four patients with MRSA bacteremia, including 31 with a high vancomycin MIC and 63 with a low MIC were analyzed. There was no significant difference between the presence of agr dysfunction and SCCmec type between the two groups. A higher vancomycin MIC was not found to be associated with mortality. In contrast, high-risk bloodstream infection sources (hazard ratio [HR], 4.63; 95% confidence interval [CI] = 1.24 to 17.33) and bacterial eradication after treatment (HR, 0.06; 95% CI = 0.02 to 0.17), irrespective of vancomycin MIC, were predictors of all-cause 30-day mortality. Our study suggests that a high-risk source of bacteremia is likely to be associated with unfavorable clinical outcomes, but a high vancomycin MIC in a susceptible range, as well as genotype characteristics, are not associated with mortality.

INTRODUCTION

Staphylococcus aureus has been recognized as a major human pathogen since it was first isolated from a surgical abscess in 1880 (1). S. aureus is one of the principal causes of bacteremia, and S. aureus bacteremia (SAB) still remains a potentially fatal infection with reported mortality rates of between 13 and 34% (2, 3). During the past decade, methicillin-resistant Staphylococcus aureus (MRSA) has become a worldwide problem for clinicians, including community-associated MRSA and health care-associated MRSA disease (4).

Vancomycin, which was first used in 1958, has been a key antibiotic agent for treatment of MRSA infections. However, reduced vancomycin susceptibility in clinical isolates was reported in Japan in 1997 and considered to be associated with poor clinical outcomes in patients with MRSA bacteremia (5–7). The Clinical and Laboratory Standards Institute (CLSI) reduced the breakpoints for vancomycin against S. aureus from 4 to 2 μg/ml in 2006 (8). Although the increased vancomycin MIC is included within the susceptible range, previous reports (3, 6) have led to increased concerns about the clinical relevance of reduced vancomycin susceptibility in S. aureus. As a reflection of these concerns, some studies have focused on vancomycin MIC values at the higher end of the susceptibility range (3, 6, 7), but the relationship between isolate MIC and clinical outcomes in patients with SAB remains uncertain.

The aim of the present study was to determine the impact of MRSA bacteremia on clinical outcomes in patients with a vancomycin MIC near the upper limit of the susceptible range. The incidence, clinical characteristics, and genotypic characteristics were investigated in patients with a higher MIC and compared to a lower-MIC patient group. To further investigate the relationship between a high vancomycin MIC and the primary source of the bacteremia, we compared patients with high-risk and low-risk bacteremia sources (7).

The accessory gene regulator (agr) locus of S. aureus encodes a quorum-sensing system that coordinates the expression of virulence and other accessory genes (8). There have been some reports suggesting that agr dysfunction is associated with a decreased susceptibility of MRSA to vancomycin (9–11). To determine whether there is any link between the MIC of vancomycin and the genetic background of the patients, staphylococcal cassette chromosome mec (SCCmec) type and agr dysfunction were also examined in MRSA bloodstream isolates.

MATERIALS AND METHODS

Patients and data collection.All adult patients with an S. aureus bloodstream infection (BSI) who were hospitalized in a 2,700-bed tertiary care hospital in Seoul, South Korea, were eligible for enrollment in the present study. Consecutive SAB were collected prospectively when SAB was identified in the daily reports from the clinical microbiology unit. Corresponding clinical data, including demographic and microbiological data, were collected using computerized records. Patients with SAB were evaluated for complications associated with this condition, length of hospital stay, discharge status, and cause of death. Furthermore, clinical factors such as age, gender, underlying disease, Charlson score, and the initial manifestation of bacteremia on the calendar date of the initial blood culture were evaluated. Patients were excluded from the present study if they were outpatients or had polymicrobial infection. Only the first episode was analyzed if a patient had a recurrent episode of SAB during the study period. The study was approved by our hospital Ethical Committee.

Definitions.The duration of bacteremia was defined as the number of days between the first positive culture being taken and the last positive blood culture (12, 13). True SAB was defined in accordance with the Centers for Disease Control and Prevention criteria (14). In our institute, it has been recommended that follow-up blood culture is conducted 48 to 72 h after the initial bacteremia, with repeat blood cultures to be performed every 48 to 72 h until a negative result was obtained. The patients with MRSA bacteremia were divided into the following two groups: vancomycin MIC at the high end of the CLSI susceptibility range (MIC = 2 μg/ml) and a vancomycin MIC of <1.0 μg/ml (high- and low-MIC groups, respectively). The primary source of bacteremia was divided into the three categories described elsewhere (7). A low-risk source was defined by a related mortality rate of <10% and includes intravenous catheter, urinary tract infection, gynecologic sources, and the ear, nose, or larynx. A mortality rate of 10 to 20% was used to define an intermediate-risk source, which included osteoarticular sources, soft tissue sources, and unknown sources. High-risk sources, associated with a >20% mortality rate, included endovascular sources, the lower respiratory tract, abdominal sources, and central nervous system foci. The primary foci of infections, including catheter-related bacteremia (15) and the presence of pneumonia (16, 17), were defined according to generally accepted criteria.

When the source of infection was not determined by clinical and microbiological criteria, it was considered unknown (6). Bloodstream infections were considered to be health care associated when there was hospitalization or health care contact in the 30 days prior to the onset of bacteremia. Prior antibiotic therapy was defined as the use of any antibiotics for more than 48 h within 3 months before the occurrence of the bacteremic episode. Prior vancomycin therapy was defined as the use of vancomycin for more than 48 h during the month prior to the occurrence of the bacteremia. Empirical vancomycin therapy was defined as the vancomycin administered within 48 h after blood culture. A 30-day mortality outcome was defined as death within 30 days of an index S. aureus blood culture.

Microbiological tests.Strain identification and antimicrobial susceptibilities of S. aureus were determined using the MicroScan PBC 28 panel (Siemens, West Sacramento, CA), which contained six vancomycin wells with different concentrations ranging from 0.5 to 16 μg/ml. The function of the agr operon was measured through an analysis of delta-hemolysin production on blood agar plates using S. aureus RN4220, as described elsewhere (18). The presence of synergistic hemolysis made by the interaction of the beta-hemolysin indicates the delta-hemolysin production by the test organism that means the existence of a functional agr locus (19, 20). agr dysfunction was defined as the complete absence of enhancement by delta-hemolysin within the beta-hemolytic zone (8–11). Eight loci selected on the basis of previously described mec element sequences and an internal positive control of the mecA gene were included in multiplex PCR experiments to determine SCCmec type for MRSA isolates (21). All tests were performed in the absence of any information regarding the S. aureus bacteremia.

Statistical analysis.All statistical analyses were performed using SAS software (version 9.1; SAS Institute, Inc., Cary, NC). Categorical variables were compared using the Fisher exact test or the Pearson χ2 test, as appropriate, and continuous variables were compared using the Kruskal-Wallis test. To evaluate the effects of isolates with different vancomycin MIC levels on mortality, relative risks, and 95% confidence intervals (CI) were calculated as hazard ratios (HRs) derived from the Cox proportional-hazards regression model. Multivariable models were fitted using available clinical covariates, and analysis using a backward elimination model was then performed. P values of ≤0.05 were considered to be statistically significant.

RESULTS

Study population.A total of 190 adult patients in our institution were identified with S. aureus bacteremia between May 2010 and June 2012. Of these patients, 96 cases were excluded from our current analysis because they had methicillin-susceptible S. aureus bacteremia (MSSA) or polymicrobial infections. The final cohort included 94 patients with MRSA bacteremia, of which 31 (33%) were classified with MRSA bacteremia with a vancomycin MIC near to the upper limit of the susceptible range (MIC = 2 μg/ml). The remaining 63 (67%) patients were assigned to the low-MIC group (MIC ≤ 1.0 μg/ml). Table 1 lists the baseline characteristics of these subject patients. The two study groups were similar in baseline characteristics. In addition, there was no difference of the mean duration of follow-up days after the initial bacteremia between the high- and low-MIC groups (median 2.8 days versus 3.0 days, respectively, P = 0.88). The proportions of patients with high-risk (23% versus 21%), intermediate-risk (45% versus 41%), or low-risk (32% versus 38%) sources of MRSA were similar between the high- and low-MIC groups. The frequency of prior vancomycin exposure did not differ between the two groups (P = 0.08). However, the overall frequency of prior antibiotic exposure was higher for patients in the high-vancomycin-MIC group than in the low-MIC group (87% versus 59%, P = 0.006).

View this table:
  • View inline
  • View popup
Table 1

Baseline characteristics and clinical courses of patients with S. aureus bacteremia

Clinical outcomes between the high- and low-MIC groups.There was no significant difference found in the total duration of antibiotics therapy between the high- and low-MIC groups (median 19 days versus 14 days, P = 0.74). Twenty-two (71%) isolates with a high MIC and 48 (76%) with a low MIC showed negative results in a follow-up culture. The 30-day mortality for the whole group was 22.3% (21/94), but there were no significant differences in attributable mortality or 30-day mortality between the two groups.

Genotype characteristics.Table 2 reports the genotypic characteristics of MRSA isolates from the high-MIC or low-MIC groups. Most isolates were found to be associated with SCCmec type II in both groups (84 and 68%, respectively). Genotype analysis of the agr locus showed that 77% of the high-MIC patients and 67% of the low-MIC patients belonged to agr group II. A total of 23% of the isolates in the high-MIC group (n = 7) and 35% in the low-MIC group (n = 22) had an agr dysfunction (P = 0.22).

View this table:
  • View inline
  • View popup
Table 2

Genotypic characteristics of S. aureus bacteremia

Clinical characteristics and outcomes according to the bacteremia source.The main clinical characteristics of the MRSA bacteremia cases in our study population according to the primary source of their bacteremia are indicated in Table 3. Thirty-four patients had a low-risk source of bacteremia, 40 patients had an intermediate-risk source, and 20 patients had a high-risk source. The clinical characteristics of patients were similar between patient groups. The percentage of isolates in patients with a vancomycin MIC of 2 μg/ml also did not differ among the three groups (29% in the low-risk group, 35% in the intermediate-risk group, and 35% in the high-risk group). A total of 29 isolates had an agr dysfunction: 8 isolates (24%) in the low-risk group, 17 isolates (43%) in the intermediate-risk group, and 4 isolates (20%) in the high-risk group.

View this table:
  • View inline
  • View popup
Table 3

Clinical demographic and courses of patients with MRSA bacteremia, by source of the bacteremia

There were no differences found among the three groups in terms of the total duration of antibiotic therapy or the length of hospital stay after the onset of bacteremia. Patients with a low-risk MRSA bloodstream infection source showed increased bacterial eradication rates (82%) compared to patients having intermediate (70%) or high-risk sources (70%), but this was found not to be statistically significant. The all-cause and MRSA-associated mortality rates were both found to be higher in patients with a high-risk source of bacteremia compared to other groups; a total of 13 patients died due to MRSA bloodstream infection—6 patients (30%) in the high-risk source group, 5 patients (13%) in the intermediate-risk group, and 2 patients (6%) in the low-risk source group (P = 0.004).

Predictors of mortality.By univariate analysis, a history of hospitalization, intensive care unit admission at the time of the initial bacteremia, initial septic shock, the source of bacteremia, and bacterial eradication after treatment were shown to be associated with overall mortality (Table 4). By multivariate analysis, bacterial eradication after treatment (hazard ratio [HR], 0.06; 95% CI = 0.02 to 0.17), and a high-risk source of bacteremia (HR, 4.63; 95% CI = 1.24 to 17.33) were found to be independently associated with overall mortality, whereas a vancomycin MIC of 2 μg/ml was dropped out the model. Factors associated with attributable mortality identified by univariate analysis—initial septic shock, a high-risk source of bacteremia, empirical vancomycin therapy, and bacterial eradication after treatment—were found to be associated with attributable 30-day mortality (HR, 0.04; 95% CI = 0.01 to 0.15 [P < 0.001]). In multivariate analysis, the association between bacterial eradication (HR, 0.04; 95% CI = 0.01 to 0.15 [P < 0.001]) and an attributable 30-day mortality remained significant.

View this table:
  • View inline
  • View popup
Table 4

Factors associated with crude 30-day mortality by Cox proportional hazard regression with univariate and multivariate modelsa

DISCUSSION

Infections caused by MRSA remain a major disease burden in community and hospital patient populations. Vancomycin has been the treatment cornerstone for MRSA infections, but there are increasing concerns regarding its clinical usefulness in the treatment of serious MRSA infections. In present analyses, we found that MRSA bacteremia cases with a high vancomycin MIC did not show a higher mortality rate. High-risk bloodstream infection sources of MRSA were found to be a main predictor of overall mortality outcomes, irrespective of the vancomycin MIC level.

Understanding the impact of MRSA infections on outcomes in patients with a higher vancomycin MIC within the susceptible range is important to the treating clinicians. Thus, a number of interesting studies on this issue have been reported in recent years (3, 6, 7, 21–24). However, controversy remains regarding the effects of vancomycin on MRSA infection in patients with reduced vancomycin susceptibility.

In a study by Holmes et al. (3), a vancomycin MIC of >1.5 μg/ml was found to be associated with a higher mortality, but this relationship was not found to be related to the antibiotic treatment received (flucloxacillin or vancomycin). Lodise et al. observed that MRSA bloodstream infections in patients with a higher vancomycin MIC (≥1.5 mg/liter) had a higher likelihood of treatment failure, including persistent bacteremia and a recurrence of MRSA bacteremia (6).

However, in a previous study by Neuner et al., a high vancomycin MIC (2 μg/ml) was found to be associated with persistent bacteremia but with no increase in hospital mortality (24). Interestingly, there are similarities between our current study findings and those of Honda et al. (22), which indicated a relationship between reduced vancomycin susceptibility and 28-day mortality among a cohort of patients with MRSA bacteremia. The Honda study reported that a vancomycin MIC ≥2 μg/ml is not associated with mortality (HR, 1.57; 95% CI = 0.73 to 3.37) after adjusting for underlying patient factors.

Several possible explanations exist for the discordant findings among these previous studies. First, there may be geographical variations in pathogen-specific factors, including polymorphisms at the agr locus. Molecular studies can help to uncover the impact of clonal differences on treatment failure in MRSA infections with reference to the vancomycin MIC. We have examined some of the genetic characteristics of all isolates from MRSA cases at our institution, while most previous studies have not evaluated the molecular characteristics of such infections (21).

The relationship between specific microbiological factors and MRSA isolates in cases where isolates showed a reduced vancomycin susceptibility, and the impact of this on clinical outcomes still remains unclear. Han et al. (25) recently reported that MRSA isolates characterized by a reduced vancomycin susceptibility (MIC > 1.0 mg/liter) are significantly associated with SCCmec type II but not with agr dysfunction. Furthermore, the data presented did not demonstrate vancomycin failure or persistent bacteremia. In our present study, a high vancomycin MIC was not found to be associated with specific SCCmec type or agr dysfunction. Furthermore, we did not find that the SCCmec type or agr dysfunction is associated with increased mortality in MRSA bacteremia. Recently, Nienaber et al. demonstrated that clonal complex 30 genotype was associated with an increased risk for S. aureus infective endocarditis (26). Thus, further research into organism factors, including the molecular epidemiology of MRSA as well as genome comparison, will be needed to elucidate virulence factors and determine the optimal treatments for this condition.

A second explanation for the discordant results may be due to methodological differences between prior studies. Some studies included patients that did not have bacteremia but had other diseases, such as pneumonia (27), or that had MSSA bacteremia (3, 28) and applied different separation criteria for the vancomycin MIC levels (i.e., including an MIC ≥ 2 μg/ml) (22). Furthermore, the lack of information concerning the severity of infection and source control has also produced conflicting results in the past (29). It is thus likely that not only pathogen-specific factors but also patient factors are responsible for differing clinical outcomes of MRSA infections. Further studies are needed to examine these parameters.

It has remained unclear to date whether a low-risk BSI has comparable results to a high-risk BSI (21). In our present study, we decided to evaluate the impact of the primary source of the bacteremia on mortality outcomes in patients with a high vancomycin MIC since no previous study has stratified MIC data in this way. Our findings demonstrate that a high-risk source of bacteremia, such as endocarditis, pneumonia, and meningitis, is predictive of an overall 30-day mortality associated with MRSA BSI (HR, 4.63; 95% CI = 1.24 to 17.33, P = 0.02). Our results further suggest that earlier identification of the primary source of bacteremia is important in reducing the mortality associated with MRSA.

Our study has some limitations. The MRSA data were obtained from patients in a single center and thus will not reflect possible institutional differences. This may limit their applicability to other hospitals. There was no assessment of heteroresistant vancomycin-intermediate S. aureus (hVISA) infections in our analyses. However, in a study by Musta et al. (30), the hVISA frequency was MIC dependent, and the status of hVISA was not associated with mortality or persistent bacteremia in a multivariate analysis. Similarly, previous studies, including those performed at our center (31–35), have shown that hVISA is not associated with higher mortality following vancomycin therapy. The diverse prevalence of hVISA reported in different articles (from 0% to >50%) also makes it difficult to evaluate the importance of hVISA in clinical settings (7). Finally, MicroScan was used as an MIC testing methodology in this study. Etest is generally used in analysis for MRSA bacteremia, but some authors have shown that the MicroScan can be an appropriate method for testing S. aureus susceptibility (36, 37). In the present study, we essentially tested the impact of a vancomycin MIC near the upper range of susceptibility on outcomes in the clinical setting. Because there is a paucity of available data using MicroScan, studies such as ours will be needed to help in important clinical decision making.

Recently, guidelines from the Infectious Diseases Society of America have recommended that the patient's clinical response to treatment should determine the continued use of vancomycin, independent of the MIC, when isolates show an vancomycin MIC of ≤2 μg/ml (38). Our current data accord with this MRSA recommendation. By extension, these findings imply that the choice of antibiotics for the treatment of MRSA bacteremia might be based on the degree of risk in terms of the primary source, especially in patients who have a high-risk source of MRSA. This will be valuable information for the treating physician, because there are currently no satisfactory alternatives to vancomycin for the treatment of MRSA bacteremia. Although concerns regarding increasing vancomycin MIC levels have led to a preference among clinicians for alternative therapies such as daptomycin, linezolid, and telavancin, there are currently no head-to-head trials under way to elucidate the effectiveness of these antibiotics against MRSA. Furthermore, treatment failures for daptomycin, based on a cross-resistance of MRSA isolates with a high vancomycin MIC to this drug, have been reported (39, 40). Our current findings have implications for clinicians in countries where daptomycin is not approved, including South Korea. Further data are needed to determine whether the optimization of therapies in accordance with the primary sources of MRSA infection can improve clinical outcomes in affected patients.

In conclusion, we found in our current analysis that a high vancomycin MIC within the susceptible range is not associated with significant differences in the overall 30-day mortality or attributable mortality outcomes in patients with MRSA bacteremia. Our data indicate that a high-risk source of bacteremia is likely to be associated with an unfavorable clinical outcome, but that genotype characteristics such as the SCCmec type and agr dysfunction are not associated with mortality. A randomized trial is needed to assess the role of primary sources of MRSA in patient outcomes, especially in cases with a high vancomycin MIC, and to determine effective treatment options.

ACKNOWLEDGMENTS

We have no potential conflicts of interest, and there is no financial support to report.

FOOTNOTES

    • Received 29 May 2013.
    • Returned for modification 21 July 2013.
    • Accepted 18 August 2013.
    • Accepted manuscript posted online 26 August 2013.
  • Copyright © 2013, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Howden BP,
    2. Davies JK,
    3. Johnson PD,
    4. Stinear TP,
    5. Grayson ML
    . 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99–139.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Jensen AG,
    2. Wachmann CH,
    3. Espersen F,
    4. Scheibel J,
    5. Skinhøj P,
    6. Frimodt-Møller N
    . 2002. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch. Intern. Med. 162:25–32.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Holmes NE,
    2. Turnidge JD,
    3. Munckhof WJ,
    4. Robinson JO,
    5. Korman TM,
    6. O'Sullivan MV,
    7. Anderson TL,
    8. Roberts SA,
    9. Gao W,
    10. Christiansen KJ,
    11. Coombs GW,
    12. Johnson PD,
    13. Howden BP
    . 2011. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J. Infect. Dis. 204:340–347.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Klevens RM,
    2. Morrison MA,
    3. Nadle J,
    4. Petit S,
    5. Gershman K,
    6. Ray S,
    7. Harrison LH,
    8. Lynfield R,
    9. Dumyati G,
    10. Townes JM,
    11. Craig AS,
    12. Zell ER,
    13. Fosheim GE,
    14. McDougal LK,
    15. Carey RB,
    16. Fridkin SK
    , Active Bacterial Core surveillance (ABCs) MRSA Investigators. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763–1771.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Howden BP,
    2. Ward PB,
    3. Charles PG,
    4. Korman TM,
    5. Fuller A,
    6. du Cros P,
    7. Grabsch EA,
    8. Roberts SA,
    9. Robson J,
    10. Read K,
    11. Bak N,
    12. Hurley J,
    13. Johnson PD,
    14. Morris AJ,
    15. Mayall BC,
    16. Grayson ML
    . 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521–528.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Lodise TP,
    2. Graves J,
    3. Evans A,
    4. Graffunder E,
    5. Helmecke M,
    6. Lomaestro BM,
    7. Stellrecht K
    . 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315–3320.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Soriano A,
    2. Marco F,
    3. Martínez JA,
    4. Pisos E,
    5. Almela M,
    6. Dimova VP,
    7. Alamo D,
    8. Ortega M,
    9. Lopez J,
    10. Mensa J
    . 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193–200.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Novick RP,
    2. Geisinger E
    . 2008. Quorum sensing in staphylococci. Annu. Rev. Genet. 42:541–564.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Sakoulas G,
    2. Moellering RC Jr,
    3. Eliopoulos GM
    . 2006. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis. 42(Suppl 1)]?:S40–S50.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Jang HC,
    2. Kang SJ,
    3. Choi SM,
    4. Park KH,
    5. Shin JH,
    6. Choy HE,
    7. Jung SI,
    8. Kim HB
    . 2012. Difference in agr dysfunction and reduced vancomycin susceptibility between MRSA bacteremia involving SCCmec types IV/IVa and I-III. PLoS One 7:e49136. doi:10.1371/journal.pone.0049136.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Seidl K,
    2. Chen L,
    3. Bayer AS,
    4. Hady WA,
    5. Kreiswirth BN,
    6. Xiong YQ
    . 2011. Relationship of agr expression and function with virulence and vancomycin treatment outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 55:5631–5639.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Fowler VG Jr,
    2. Sakoulas G,
    3. McIntyre LM,
    4. Meka VG,
    5. Arbeit RD,
    6. Cabell CH,
    7. Stryjewski ME,
    8. Eliopoulos GM,
    9. Reller LB,
    10. Corey GR,
    11. Jones T,
    12. Lucindo N,
    13. Yeaman MR,
    14. Bayer AS
    . 2004. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J. Infect. Dis. 190:1140–1149.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Hawkins C,
    2. Huang J,
    3. Jin N,
    4. Noskin GA,
    5. Zembower TR,
    6. Bolon M
    . 2007. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch. Intern. Med. 167:1861–1867.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Garner JS,
    2. Jarvis WR,
    3. Emori TG,
    4. Horan TC,
    5. Hughes JM
    . 1988. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control 16:128–140.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Mermel LA,
    2. Allon M,
    3. Bouza E,
    4. Craven DE,
    5. Flynn P,
    6. O'Grady NP,
    7. Raad II,
    8. Rijnders BJ,
    9. Sherertz RJ,
    10. Warren DK
    . 2009. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49:1–45.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Mandell LA,
    2. Wunderink RG,
    3. Anzueto A,
    4. Bartlett JG,
    5. Campbell GD,
    6. Dean NC,
    7. Dowell SF,
    8. File TM Jr,
    9. Musher DM,
    10. Niederman MS,
    11. Torres A,
    12. Whitney CG
    , Infectious Diseases Society of America, American Thoracic Society. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44:S27–S72.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Park SY,
    2. Park HJ,
    3. Moon SM,
    4. Park KH,
    5. Chong YP,
    6. Kim MN,
    7. Kim SH,
    8. Lee SO,
    9. Kim YS,
    10. Woo JH,
    11. Choi SH
    . 2012. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. BMC Infect. Dis. 12:308. doi:10.1186/1471-2334-12-308.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Gilot P,
    2. Lina G,
    3. Cochard T,
    4. Poutrel B
    . 2002. Analysis of the genetic variability of genes encoding the RNA III-activating components Agr and TRAP in a population of Staphylococcus aureus strains isolated from cows with mastitis. J. Clin. Microbiol. 40:4060–4067.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Park SY,
    2. Chong YP,
    3. Park HJ,
    4. Park KH,
    5. Moon SM,
    6. Jeong JY,
    7. Kim MN,
    8. Kim SH,
    9. Lee SO,
    10. Choi SH,
    11. Woo JH,
    12. Kim YS
    . 2013. agr dysfunction and persistent methicillin-resistant Staphylococcus aureus bacteremia in patients with removed eradicable foci. Infection 41:111–119.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Sakoulas G,
    2. Eliopoulos GM,
    3. Moellering RC Jr,
    4. Wennersten C,
    5. Venkataraman L,
    6. Novick RP,
    7. Gold HS
    . 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492–1502.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. van Hal SJ,
    2. Lodise TP,
    3. Paterson DL
    . 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54:755–771.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Honda H,
    2. Doern CD,
    3. Michael-Dunne W Jr,
    4. Warren DK
    . 2011. The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin-resistant Staphylococcus aureus bacteremia. BMC Infect. Dis. 11:335. doi:10.1186/1471-2334-11-335.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Wi YM,
    2. Kim JM,
    3. Joo EJ,
    4. Ha YE,
    5. Kang CI,
    6. Ko KS,
    7. Chung DR,
    8. Song JH,
    9. Peck KR
    . 2012. High vancomycin minimum inhibitory concentration is a predictor of mortality in methicillin-resistant Staphylococcus aureus bacteremia. Int. J. Antimicrob. Agents 40:108–113.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Neuner EA,
    2. Casabar E,
    3. Reichley R,
    4. McKinnon PS
    . 2010. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagn. Microbiol. Infect. Dis. 67:228–233.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Han JH,
    2. Edelstein PH,
    3. Lautenbach E
    . 2012. Reduced vancomycin susceptibility and staphylococcal cassette chromosome mec (SCCmec) type distribution in methicillin-resistant Staphylococcus aureus bacteremia. J. Antimicrob. Chemother. 67:2346–2349.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Nienaber JJ,
    2. Sharma Kuinkel BK,
    3. Clarke-Pearson M,
    4. Lamlertthon S,
    5. Park L,
    6. Rude TH,
    7. Barriere S,
    8. Woods CW,
    9. Chu VH,
    10. Marín M,
    11. Bukovski S,
    12. Garcia P,
    13. Corey GR,
    14. Korman T,
    15. Doco-Lecompte T,
    16. Murdoch DR,
    17. Reller LB,
    18. Fowler VG Jr
    , International Collaboration on Endocarditis-Microbiology Investigators. 2011. Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. J. Infect. Dis. 204:704–713.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Hidayat LK,
    2. Hsu DI,
    3. Quist R,
    4. Shriner KA,
    5. Wong-Beringer A
    . 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138–2144.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Price J,
    2. Atkinson S,
    3. Llewelyn M,
    4. Paul J
    . 2009. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin. Infect. Dis. 48:997–998.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Deresinski S
    . 2012. Methicillin-resistant Staphylococcus aureus and vancomycin: minimum inhibitory concentration matters. Clin. Infect. Dis. 54:772–774.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Musta AC,
    2. Riederer K,
    3. Shemes S,
    4. Chase P,
    5. Jose J,
    6. Johnson LB,
    7. Khatib R
    . 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47:1640–1644.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Maor Y,
    2. Hagin M,
    3. Belausov N,
    4. Keller N,
    5. Ben-David D,
    6. Rahav G
    . 2009. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199:619–624.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Park KH,
    2. Kim ES,
    3. Kim HS,
    4. Park SJ,
    5. Bang KM,
    6. Park HJ,
    7. Park SY,
    8. Moon SM,
    9. Chong YP,
    10. Kim SH,
    11. Lee SO,
    12. Choi SH,
    13. Jeong JY,
    14. Kim MN,
    15. Woo JH,
    16. Kim YS
    . 2012. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteremia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus. J. Antimicrob. Chemother. 67:1843–1849.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Khatib R,
    2. Jose J,
    3. Musta A,
    4. Sharma M,
    5. Fakih MG,
    6. Johnson LB,
    7. Riederer K,
    8. Shemes S
    . 2011. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteremia. J. Antimicrob. Chemother. 66:1594–1599.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Satola SW,
    2. Lessa FC,
    3. Ray SM,
    4. Bulens SN,
    5. Lynfield R,
    6. Schaffner W,
    7. Dumyati G,
    8. Nadle J,
    9. Patel JB
    , Active Bacterial Core surveillance (ABCs) MRSA Investigators. 2011. Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. aureus phenotype. J. Clin. Microbiol. 49:1583–1587.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Kim MN,
    2. Hwang SH,
    3. Pyo YJ,
    4. Mun HM,
    5. Pai CH
    . 2002. Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. J. Clin. Microbiol. 40:1376–1380.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Ji M,
    2. Lee M,
    3. Noh S,
    4. Kim MN
    . 2010. Evaluation of the performance of the MicroScan Pos Breakpoint Combo Panel Type 28 for susceptibility testing of Staphylococcus aureus: low-range minimum inhibitory concentration of vancomycin, cefoxitin screening, and inducible clindamycin resistance detection. Korean J. Lab. Med. 30:637–646.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Kruzel MC,
    2. Lewis CT,
    3. Welsh KJ,
    4. Lewis EM,
    5. Dundas NE,
    6. Mohr JF,
    7. Armitige LY,
    8. Wanger A
    . 2011. Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 49:2272–2273.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Liu C,
    2. Bayer A,
    3. Cosgrove SE,
    4. Daum RS,
    5. Fridkin SK,
    6. Gorwitz RJ,
    7. Kaplan SL,
    8. Karchmer AW,
    9. Levine DP,
    10. Murray BE,
    11. Rybak JM,
    12. Talan DA,
    13. Chambers HF
    . 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executivei summary. Clin. Infect. Dis. 52:285–292.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Moise PA,
    2. North D,
    3. Steenbergen JN,
    4. Sakoulas G
    . 2009. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect. Dis. 9:617–624.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. van Hal SJ,
    2. Paterson DL,
    3. Gosbell IB
    . 2011. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteremia in a daptomycin-naive patient-a review of the literature. Eur. J. Clin. Microbiol. Infect. Dis. 30:603–610.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
Impact of Reduced Vancomycin MIC on Clinical Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia
So-Youn Park, In-Hwan Oh, Hee-Joo Lee, Chun-Gyoo Ihm, Jun Seong Son, Mi Suk Lee, Mi-Na Kim
Antimicrobial Agents and Chemotherapy Oct 2013, 57 (11) 5536-5542; DOI: 10.1128/AAC.01137-13

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Impact of Reduced Vancomycin MIC on Clinical Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Impact of Reduced Vancomycin MIC on Clinical Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia
So-Youn Park, In-Hwan Oh, Hee-Joo Lee, Chun-Gyoo Ihm, Jun Seong Son, Mi Suk Lee, Mi-Na Kim
Antimicrobial Agents and Chemotherapy Oct 2013, 57 (11) 5536-5542; DOI: 10.1128/AAC.01137-13
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596